Literature DB >> 1910647

Autonomic dysreflexia. A survey of current treatment.

R L Braddom1, J F Rocco.   

Abstract

Autonomic dysreflexia (AD) is a syndrome that often occurs in patients with spinal cord injuries above T-6 and can have life-threatening results if not properly managed. The hypertension associated with AD can cause a great deal of morbidity and mortality, requiring quick and effective blood pressure reduction. Both pharmacologic and nonpharmacologic methods are used to prevent or alleviate the symptoms associated with an acute episode of AD. We found that current literature is lacking in controlled, prospective, randomized studies comparing the efficacy of various medications used in the treatment of AD. We conducted a nationwide survey to determine the consensus among clinicians concerning the management of AD. The survey was designed to determine the current clinical status of AD, to assess methods of treatment being used and to summarize and give a rationale for the drugs most commonly prescribed. Finally, a suggestion for a wallet-sized card briefly outlining effective treatments of AD in an emergency situation is included. Results indicate that most clinicians feel that after nonpharmacologic measures have failed, antihypertensive medication is useful in controlling the symptoms of AD while the inciting cause is being found and treated. Agents used most frequently include, but are not limited to, nifedipine, phenoxybenzamine, prazosin, mecamylamine and nitrates.

Entities:  

Mesh:

Year:  1991        PMID: 1910647

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  24 in total

Review 1.  The physically-challenged athlete: medical issues and assessment.

Authors:  K L Dec; K J Sparrow; D B McKeag
Journal:  Sports Med       Date:  2000-04       Impact factor: 11.136

Review 2.  Autonomic dysreflexia: a medical emergency.

Authors:  J Bycroft; I S Shergill; E A L Chung; E A L Choong; N Arya; P J R Shah
Journal:  Postgrad Med J       Date:  2005-04       Impact factor: 2.401

Review 3.  A systematic review of the management of autonomic dysreflexia after spinal cord injury.

Authors:  Andrei Krassioukov; Darren E Warburton; Robert Teasell; Janice J Eng
Journal:  Arch Phys Med Rehabil       Date:  2009-04       Impact factor: 3.966

4.  Autonomic dysreflexia in a man with multiple sclerosis.

Authors:  Duygu Geler Kulcu; Berfu Akbas; Beyza Citci; Mutlu Cihangiroglu
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

Review 5.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

6.  Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows: Management of Blood Pressure, Sweating, and Temperature Dysfunction.

Authors:  Andrei Krassioukov; Todd A Linsenmeyer; Lisa A Beck; Stacy Elliott; Peter Gorman; Steven Kirshblum; Lawrence Vogel; Jill Wecht; Sarah Clay
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

Review 7.  Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management.

Authors:  Khalid C Eldahan; Alexander G Rabchevsky
Journal:  Auton Neurosci       Date:  2017-05-08       Impact factor: 3.145

8.  Hemorrhoidal bleeding in chronic spinal cord injury: results of multiple banding.

Authors:  B C Cosman; D A Eastman; I Perkash; J M Stone
Journal:  Int J Colorectal Dis       Date:  1994       Impact factor: 2.571

9.  Prevention of recurrent autonomic dysreflexia: a survey of current practice.

Authors:  Deborah Caruso; David Gater; Christopher Harnish
Journal:  Clin Auton Res       Date:  2015-08-18       Impact factor: 4.435

10.  Online training improves paramedics' knowledge of autonomic dysreflexia management guidelines.

Authors:  K A Martin Ginis; J R Tomasone; M Welsford; K Ethans; A R Sinden; M Longeway; A Krassioukov
Journal:  Spinal Cord       Date:  2016-09-13       Impact factor: 2.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.